Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study

An extrafine formulation of the long-acting muscarinic antagonist glycopyrronium bromide (GB) is in development for chronic obstructive pulmonary disease (COPD), in combination with beclometasone dipropionate and formoterol fumarate – a “fixed triple”. This two-part study was randomized, double blin...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Scuri, Mario, Collarini, Sara, Vezzoli, Stefano, Mariotti, Fabrizia, Muraro, Annamaria, Acerbi, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511020/
https://www.ncbi.nlm.nih.gov/pubmed/28744115
http://dx.doi.org/10.2147/COPD.S137659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511020/
https://www.ncbi.nlm.nih.gov/pubmed/28744115
http://dx.doi.org/10.2147/COPD.S137659

Ejemplares similares